Wuhan YZY Biopharma Co., Ltd. (SEHK: 2496)
Health Care · Biotechnology · CN
HK$3.60
-1.37% today · -36.4% 1Y
Wuhan YZY Biopharma Co., Ltd. (SEHK: 2496) operates in the Biotechnology industry within the Health Care sector. The company is valued at $88.93M and employs 106 people.
Over the last twelve months the share price has lost 36.4%, trading between 3.60 and 8.40.
Tweenvest scores Wuhan YZY Biopharma Co., Ltd. across four factors: quality 13/100, value 49/100. Its strongest factor is value.
2496 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $88.93M
- Revenue (TTM)
- $9.56M
- P/E
- —
- EPS
- -0.44
- Dividend yield
- —
- Beta (5Y)
- 0.50
- 52-week high
- HK$8.40
- 52-week low
- HK$3.60
- Avg volume (3M)
- —
- Shares outstanding
- 193.85M
- Employees
- 106
- Next earnings
- —
About Wuhan YZY Biopharma Co., Ltd.
Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the development of bispecific antibody-based treatments. Its therapeutic focus areas include various cancers, their associated complications, and age-related ophthalmic conditions. The company's extensive portfolio of drug candidates aims to address a wide range of diseases, such as malignant ascites, malignant pleural effusion, various solid tumors (including pancreatic cancer, hepatocellular carcinoma, other advanced solid tumors, and HER2-positive solid tumors), small cell lung cancer, and relapsed/refractory multiple myeloma. Additionally, they are advancing therapies for COVID-19 and several eye disorders like wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and other conditions characterized by abnormal blood vessel formation in the eye. The company, established in 2010, is headquartered in Wuhan, China.
- ISIN
- CNE1000063C4
- Founded
- 2010
- Listed since
- Sep 26, 2023
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.